Advertisement

U.S. markets open in 8 hours 14 minutes

S&P Futures
4,020.25
+19.00(+0.47%)
Dow Futures
32,567.00
+133.00(+0.41%)
Nasdaq Futures
12,939.50
+49.25(+0.38%)
Russell 2000 Futures
1,759.10
+11.40(+0.65%)
Crude Oil
69.39
+0.13(+0.19%)
Gold
1,974.70
-9.10(-0.46%)

Advertisement

Athersys, Inc. (ATHX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Visitors trend2W10W9M

1.3500

-0.1000

(-6.90%)

At close: 04:00PM EDT

1.4100

+0.06

(+4.44%)

After hours:

06:44PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Slow Stochastic

View all chart patterns

Performance Outlook

Previous Close	1.4500
Open	1.4600
Bid	1.3500 x 3000
Ask	1.4100 x 1000
Day's Range	1.3000 - 1.5300
52 Week Range	0.5000 - 33.2500
Volume	221,465
Avg. Volume	292,113

Market Cap	23.232M
Beta (5Y Monthly)	-0.74
PE Ratio (TTM)	0.81
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATHX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Athersys, Inc.
Analyst Report: Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Rating
Fair Value
Economic Moat
4 days agoMorningstar

News

American City Business Journals
Athersys is a 'very different company' from a year ago, CEO says
In June 2022, Athersys embarked on a financial and operational restructuring to lower its cost and conserve cash while completing the testing and commercialization of its adult stem-cell therapy.
American City Business Journals
Athersys shares take a wild ride while executives meet with investors
If the company's stock price stays above $1 for 10 consecutive business days, Athersys will regain compliance with a Nasdaq listing requirement.
American City Business Journals
Athersys shares rise as company managers meet with investors
For most of the last year, clinical-stage Athersys has been cutting costs to preserve its capital while looking for new partners to help launch its adult stem cell therapy.

Advertisement

S&P Futures4,020.25+19.00(+0.47%)

Dow Futures32,567.00+133.00(+0.41%)

Nasdaq Futures12,939.50+49.25(+0.38%)

Russell 2000 Futures1,759.10+11.40(+0.65%)

Crude Oil69.39+0.13(+0.19%)

Gold1,974.70-9.10(-0.46%)

Athersys, Inc. (ATHX)

Chart Events

Performance Outlook

Fair Value

Related Research

Athersys is a 'very different company' from a year ago, CEO says

Athersys shares take a wild ride while executives meet with investors

Athersys shares rise as company managers meet with investors

S&P Futures
4,020.25
+19.00(+0.47%)

Dow Futures
32,567.00
+133.00(+0.41%)

Nasdaq Futures
12,939.50
+49.25(+0.38%)

Russell 2000 Futures
1,759.10
+11.40(+0.65%)

Crude Oil
69.39
+0.13(+0.19%)

Gold
1,974.70
-9.10(-0.46%)